A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma

Share :
Published: 13 Jun 2022
Views: 79
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain

Dr Carlos Fernandez De Larrea presents data from the multicentre CARTBCMA-HCB-01 study during a press conference at the EHA 2022 meeting.

The study evaluated the efficacy and safety of a novel autologous CAR T-cell product (ARI0002h) targeting B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma.

Watch Dr Fernández De Larrea's interview here

Read the news story here